Arcellx, Inc. (ACLX)
NASDAQ: ACLX · IEX Real-Time Price · USD
52.18
+2.16 (4.32%)
At close: May 1, 2024, 4:00 PM
53.21
+1.03 (1.97%)
After-hours: May 1, 2024, 4:51 PM EDT
Arcellx Revenue
In the year 2023, Arcellx had annual revenue of $110.32M. Revenue in the quarter ending December 31, 2023 was $63.15M.
Revenue (ttm)
$110.32M
Revenue Growth
n/a
P/S Ratio
24.97
Revenue / Employee
$848,608
Employees
130
Market Cap
2.75B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 110.32M | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neogen | 929.24M |
| GoodRx Holdings | 750.27M |
| ACADIA Pharmaceuticals | 726.44M |
| Certara | 354.34M |
| Arrowhead Pharmaceuticals | 181.74M |
| Olink Holding AB (publ) | 169.60M |
| Merus | 43.95M |
| CG Oncology | 204.00K |
ACLX News
- 27 days ago - Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 6 weeks ago - Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - Business Wire
- 2 months ago - Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference - PRNewsWire
- 2 months ago - Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights - PRNewsWire
- 5 months ago - Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH - PRNewsWire
- 6 months ago - Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium - Market Watch
- 6 months ago - Kite and Arcellx Announce Expansion in Strategic Partnership - Business Wire
- 6 months ago - ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP - PRNewsWire